Celixir Limited

If at first you don’t succeed, narrow down the population and try again. This is what BioCardia did last month, beginning a new Phase III trial of its autologous CardiAMP cell therapy in heart failu

Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of t

IN VITRO DIAGNOSTICS Mergers & Acquisitions Luminex Corp. Nanosphere Inc. Luminex Corp. is paying $77mm ($1.70 per share; a 63% premium) in cash to acquire molecular diagnostics firm Nanosphere

Daiichi Sankyo Co. Ltd. 's move to jump-start its pipeline in the regenerative medicine area by acquiring rights in Japan to a novel cell therapy continues a trend for pharma majors in the country to